Skip to main content
Clinical Trials/NCT00990392
NCT00990392
Withdrawn
Not Applicable

Pilot Study: Topical Antibiotics for Prevention of ICU Central Line Infections

Fraser Health1 site in 1 countryNovember 2009

Overview

Phase
Not Applicable
Intervention
Polysporin Triple Therapy ointment
Conditions
Blood Stream Infections
Sponsor
Fraser Health
Locations
1
Primary Endpoint
Overall number of line related infections (local and blood borne)
Status
Withdrawn
Last Updated
10 years ago

Overview

Brief Summary

The purpose of the study is to determine if the overall central venous catheter related infection rate can be reduced by the application of Polysporin Triple Therapy ointment to the insertion site.

Detailed Description

Previous studies in the dialysis population have found a reduction in local and system central venous catheter related infections with the application of topical antibiotics to the insertion point. One such study found a mortality benefit with Polysporin Triple Therapy ointment. We intend to determine if this preparation can reduce overall line infection rates in the ICU environment through its application at the time of line insertion and twice more the following week.

Registry
clinicaltrials.gov
Start Date
November 2009
End Date
January 2011
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fraser Health
Responsible Party
Principal Investigator
Principal Investigator

Steve Reynolds

Critical care Physician

Fraser Health

Eligibility Criteria

Inclusion Criteria

  • all patients admitted to the ICU requiring a central venous catheter

Exclusion Criteria

  • previous line infection during same ICU stay
  • CVC for hemodialysis

Arms & Interventions

Polysporin Triple Therapy

Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.

Intervention: Polysporin Triple Therapy ointment

Placebo

Petroleum jelly

Intervention: Petroleum Jelly

Outcomes

Primary Outcomes

Overall number of line related infections (local and blood borne)

Time Frame: 6 months

Secondary Outcomes

  • Length of hospital stay(7 months)
  • Prevalence of methicillin-resistant Staphylococcus Aureus (MRSA)(12 months)
  • Length of ICU stay(7 months)

Study Sites (1)

Loading locations...

Similar Trials